Personal tools

Coexpression cluster:C165

From FANTOM5_SSTAR

Revision as of 13:39, 26 November 2012 by Autoedit (talk | contribs)
Jump to: navigation, search


Full id: C165_epithelioid_Adipocyte_mesothelioma_myxofibrosarcoma_lung_gastric_Mesothelial



Phase1 CAGE Peaks

Hg19::chr10:125605888..125605891,-p@chr10:125605888..125605891
-
Hg19::chr10:125605892..125605911,-p@chr10:125605892..125605911
-
Hg19::chr10:135129617..135129626,+p@chr10:135129617..135129626
+
Hg19::chr11:106426627..106426632,+p@chr11:106426627..106426632
+
Hg19::chr11:132618576..132618601,+p@chr11:132618576..132618601
+
Hg19::chr11:132618641..132618653,+p@chr11:132618641..132618653
+
Hg19::chr11:134820867..134820899,+p1@ENST00000528497
Hg19::chr11:89114727..89114730,+p@chr11:89114727..89114730
+
Hg19::chr12:54652060..54652084,-p16@CBX5
Hg19::chr13:24528588..24528596,+p@chr13:24528588..24528596
+
Hg19::chr13:27202938..27202944,-p@chr13:27202938..27202944
-
Hg19::chr14:100674067..100674074,-p@chr14:100674067..100674074
-
Hg19::chr14:64761083..64761101,-p1@ESR2
Hg19::chr14:64761275..64761283,-p14@ESR2
Hg19::chr15:95590268..95590274,-p@chr15:95590268..95590274
-
Hg19::chr16:11720946..11720960,-p@chr16:11720946..11720960
-
Hg19::chr16:11720965..11720989,-p@chr16:11720965..11720989
-
Hg19::chr16:11720992..11721005,-p@chr16:11720992..11721005
-
Hg19::chr16:85360152..85360165,+p@chr16:85360152..85360165
+
Hg19::chr17:40477088..40477101,-p24@STAT3
Hg19::chr17:46719983..46720028,+p@chr17:46719983..46720028
+
Hg19::chr17:46720055..46720064,+p@chr17:46720055..46720064
+
Hg19::chr17:46783984..46784023,+p@chr17:46783984..46784023
+
Hg19::chr17:7167279..7167298,-p@chr17:7167279..7167298
-
Hg19::chr17:8774055..8774068,-p@chr17:8774055..8774068
-
Hg19::chr17:8774126..8774143,-p@chr17:8774126..8774143
-
Hg19::chr18:18711938..18711943,-p@chr18:18711938..18711943
-
Hg19::chr18:43282521..43282533,-p@chr18:43282521..43282533
-
Hg19::chr18:56495029..56495073,+p@chr18:56495029..56495073
+
Hg19::chr18:61501808..61501812,+p@chr18:61501808..61501812
+
Hg19::chr19:31630560..31630583,-p@chr19:31630560..31630583
-
Hg19::chr19:54545613..54545621,-p@chr19:54545613..54545621
-
Hg19::chr19:54545670..54545677,-p@chr19:54545670..54545677
-
Hg19::chr19:54545692..54545704,-p@chr19:54545692..54545704
-
Hg19::chr19:54545761..54545772,-p@chr19:54545761..54545772
-
Hg19::chr19:54545780..54545792,-p@chr19:54545780..54545792
-
Hg19::chr19:54545810..54545821,-p@chr19:54545810..54545821
-
Hg19::chr19:54545833..54545844,-p@chr19:54545833..54545844
-
Hg19::chr19:54598154..54598171,+p@chr19:54598154..54598171
+
Hg19::chr19:54600897..54600899,+p@chr19:54600897..54600899
+
Hg19::chr19:6600819..6600831,-p@chr19:6600819..6600831
-
Hg19::chr1:233860206..233860221,+p1@BC032032
Hg19::chr1:233860255..233860261,+p2@BC032032
Hg19::chr1:240319887..240319892,+p@chr1:240319887..240319892
+
Hg19::chr1:240320047..240320058,+p@chr1:240320047..240320058
+
Hg19::chr21:32460330..32460336,-p@chr21:32460330..32460336
-
Hg19::chr21:32526965..32526979,-p@chr21:32526965..32526979
-
Hg19::chr21:32529607..32529639,-p@chr21:32529607..32529639
-
Hg19::chr21:45175275..45175288,+p@chr21:45175275..45175288
+
Hg19::chr2:107201761..107201766,+p@chr2:107201761..107201766
+
Hg19::chr2:172271476..172271479,+p@chr2:172271476..172271479
+
Hg19::chr2:173955327..173955334,+p26@ZAK
Hg19::chr2:173955472..173955479,+p17@ZAK
Hg19::chr2:173955485..173955502,+p19@ZAK
Hg19::chr2:173955505..173955510,+p30@ZAK
Hg19::chr2:178887106..178887129,+p@chr2:178887106..178887129
+
Hg19::chr2:220548381..220548386,+p@chr2:220548381..220548386
+
Hg19::chr2:75145535..75145551,+p4@ENST00000435984
Hg19::chr3:153575775..153575789,+p@chr3:153575775..153575789
+
Hg19::chr3:153587786..153587791,+p@chr3:153587786..153587791
+
Hg19::chr3:36170472..36170478,-p@chr3:36170472..36170478
-
Hg19::chr3:36170751..36170761,-p@chr3:36170751..36170761
-
Hg19::chr3:36170775..36170785,-p@chr3:36170775..36170785
-
Hg19::chr3:40101288..40101291,-p@chr3:40101288..40101291
-
Hg19::chr3:40118776..40118784,-p@chr3:40118776..40118784
-
Hg19::chr3:79552183..79552188,+p@chr3:79552183..79552188
+
Hg19::chr4:112993808..112993821,-p1@ENST00000511219
Hg19::chr4:138978577..138978584,+p1@ENST00000510066
Hg19::chr4:183750430..183750442,+p@chr4:183750430..183750442
+
Hg19::chr4:183750467..183750481,+p@chr4:183750467..183750481
+
Hg19::chr4:77378488..77378494,+p@chr4:77378488..77378494
+
Hg19::chr5:142023708..142023717,-p12@FGF1
Hg19::chr5:142023729..142023736,-p26@FGF1
Hg19::chr5:142023741..142023750,-p18@FGF1
Hg19::chr5:142023781..142023810,-p7@FGF1
Hg19::chr5:177989725..177989735,-p3@COL23A1
Hg19::chr6:142429681..142429688,-p@chr6:142429681..142429688
-
Hg19::chr7:137459538..137459553,-p5@DGKI
Hg19::chr7:137459557..137459587,-p3@DGKI
Hg19::chr7:157478953..157478987,-p@chr7:157478953..157478987
-
Hg19::chr7:32245227..32245235,+p@chr7:32245227..32245235
+
Hg19::chr7:68859601..68859605,+p@chr7:68859601..68859605
+
Hg19::chr7:80929708..80929725,+p@chr7:80929708..80929725
+
Hg19::chr8:100957024..100957046,+p@chr8:100957024..100957046
+
Hg19::chr8:41559667..41559679,-p@chr8:41559667..41559679
-
Hg19::chr8:67372487..67372498,+p14@C8orf46
Hg19::chr8:67372512..67372525,+p13@C8orf46
Hg19::chr8:67372527..67372543,+p11@C8orf46
Hg19::chr8:69770351..69770355,-p@chr8:69770351..69770355
-
Hg19::chr8:69961533..69961540,+p@chr8:69961533..69961540
+
Hg19::chr8:69961543..69961549,+p@chr8:69961543..69961549
+
Hg19::chr8:69961573..69961578,+p@chr8:69961573..69961578
+
Hg19::chr8:91072321..91072339,-p@chr8:91072321..91072339
-
Hg19::chr8:91110423..91110427,-p@chr8:91110423..91110427
-
Hg19::chr9:118595109..118595124,+p@chr9:118595109..118595124
+
Hg19::chr9:129142549..129142572,+p@chr9:129142549..129142572
+
Hg19::chr9:26171424..26171462,-p@chr9:26171424..26171462
-
Hg19::chr9:72658490..72658502,+p7@MAMDC2
Hg19::chr9:72658586..72658589,+p9@MAMDC2
Hg19::chr9:72658756..72658770,+p1@MAMDC2
Hg19::chr9:72658776..72658789,+p2@MAMDC2
Hg19::chr9:72833439..72833449,+p@chr9:72833439..72833449
+
Hg19::chr9:72841128..72841129,+p@chr9:72841128..72841129
+
Hg19::chr9:72841375..72841399,+p@chr9:72841375..72841399
+
Hg19::chrX:135338503..135338520,-p10@MAP7D3


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0005057receptor signaling protein activity0.00187153831806653
GO:0032147activation of protein kinase activity0.0142407650132369
GO:0030284estrogen receptor activity0.020902304528568
GO:0045860positive regulation of protein kinase activity0.020902304528568
GO:0033674positive regulation of kinase activity0.020902304528568
GO:0051347positive regulation of transferase activity0.020902304528568
GO:0007242intracellular signaling cascade0.0216310065997641
GO:0010369chromocenter0.0216310065997641
GO:0005062hematopoietin/interferon-class (D200-domain) cytokine receptor signal transducer activity0.025634107310511
GO:0045859regulation of protein kinase activity0.0289687346932396
GO:0043549regulation of kinase activity0.0289687346932396
GO:0051338regulation of transferase activity0.0289687346932396
GO:0043085positive regulation of catalytic activity0.0289687346932396
GO:0048523negative regulation of cellular process0.030519020041891
GO:0048519negative regulation of biological process0.030519020041891
GO:0030547receptor inhibitor activity0.030519020041891
GO:0048019receptor antagonist activity0.030519020041891
GO:0030545receptor regulator activity0.031699338724088
GO:0030520estrogen receptor signaling pathway0.031699338724088
GO:0000186activation of MAPKK activity0.031699338724088
GO:0005720nuclear heterochromatin0.0329309851972766
GO:0007165signal transduction0.0330777726270606
GO:0007243protein kinase cascade0.0348684891743291
GO:0004709MAP kinase kinase kinase activity0.0404629308483515
GO:0007154cell communication0.0404629308483515
GO:0008134transcription factor binding0.0404629308483515
GO:0000792heterochromatin0.0415797028128656
GO:0032502developmental process0.0415797028128656
GO:0007257activation of JNK activity0.041692835575608
GO:0000790nuclear chromatin0.0423177233929349
GO:0043507positive regulation of JNK activity0.0423177233929349
GO:0005515protein binding0.0423177233929349
GO:0043506regulation of JNK activity0.0423177233929349
GO:0000077DNA damage checkpoint0.0423177233929349
GO:0005634nucleus0.0436945181120922
GO:0031570DNA integrity checkpoint0.0447489183466585
GO:0004143diacylglycerol kinase activity0.0469213957622966
GO:0000776kinetochore0.0469213957622966
GO:0006953acute-phase response0.0471882062699121



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br><br>disease_data<br>


Disease
Ontology termp-valuen
epithelioid sarcoma5.42e-1951
mesenchymal cell neoplasm1.55e-982


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)

TF#promotersEnrichmentp-valueq-value
NFYA#4800172.983189256163045.08516815361666e-050.000866378265571893
NFYB#4801152.394256179076640.001442698631975080.00925175011819016



Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data